How GLP-1s Affect Muscles and Body Composition

How GLP-1s Affect Muscles and Body Composition

 

Key takeaways

  • GLP-1 medications can produce significant weight loss, but a portion of that loss comes from lean muscle mass, not just fat.

  • Muscle loss during rapid weight loss is a common physiological response to a calorie deficit, particularly when protein intake falls short, rather than a direct effect of the medication itself

  • Adults over 40, sedentary individuals, and those with lower baseline muscle mass face elevated risk of muscle loss when using GLP-1s.

  • A multi-pronged approach that combines adequate protein, resistance training, and gut health support can help preserve muscle while taking GLP-1 medications

Introduction

GLP-1 medicines, formally known as glucagon-like peptide-1 receptor agonists, have reshaped the treatment landscape for obesity and type 2 diabetes, with documented benefits for weight loss, glycemic control, and cardiovascular risk reduction.¹ 

As these medications move further into mainstream use, a more nuanced question has emerged: what happens to muscle mass during the rapid weight loss they produce? 

This article explains how GLP-1s affect muscle and body composition, why muscle breakdown occurs, who’s most at risk, and how a comprehensive approach can protect muscle and support healthy aging.

What GLP-1s Do in the Body and How Muscle Mass Is Impacted

Semaglutide (Ozempic, Wegovy), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) mimic GLP-1, a naturally occurring incretin hormone that regulates appetite and blood sugar. These medications delay gastric emptying, slow digestion, blunt post-meal glucose spikes, and signal satiety to the brain — collectively reducing caloric intake and, over time, producing weight loss.² 

In a sustained calorie deficit, the body draws energy from all available stores: fat and lean tissue alike. When protein intake is insufficient to meet the body's needs, it begins breaking down muscle tissue to maintain essential functions. This pattern is well documented in very low-calorie diets, low-protein diets, and post-bariatric surgery patients.³ What distinguishes GLP-1 therapy is the speed and scale of the weight loss it can produce — and that pace is where concerns about skeletal muscle loss take shape. 

Across recent clinical trials, GLP-1 therapies have proven highly effective at reducing fat mass, but up to 40% of total weight loss may consist of "fat-free mass" — a category that includes water, bone, muscle, and other lean tissue.⁴ Fat loss still outpaces muscle loss overall, so body composition shifts favorably on balance. The more pressing question is whether the lean tissue loss has a greater impact for specific populations, particularly older adults already losing muscle as part of normal aging. Emerging rodent research is also exploring downstream consequences, including slower recovery from injury.⁵ 

Who Is Most at Risk

Muscle loss during GLP-1 treatment isn’t uniform. Certain groups face a greater risk of losing higher amounts of lean muscle mass while taking GLP-1 receptor agonists. Research identifies four populations that warrant closer monitoring: 

  • Adults over 40, who are already experiencing age-related muscle decline, including those with diagnosed sarcopenia.⁶

  • Sedentary individuals, who lack the muscle-preserving stimulus that regular physical activity provides.

  • Those with low dietary protein intake, a common consequence of appetite suppression, particularly when motivation to eat is already diminished.

  • Patients undergoing rapid weight loss, where the pace of change can outstrip the body's capacity for muscle protection.

For older adults considering or currently using GLP-1 medications, even modest reductions in lean muscle mass can compound over time, elevating the risk of frailty, falls, and loss of functional independence.⁷ 

What the Research Says About Protecting Muscle Mass

Muscle loss during GLP-1 treatment is not inevitable. A growing body of research shows it can be managed with a proactive, multi-part approach. Three pillars stand out as essential components of any weight loss plan involving these medications: 

1. Resistance training is non-negotiable

Weight bearing activity – especially strength training – plays a critical role in preserving muscle during weight loss. Studies show that protein intake alone is insufficient to maintain muscle mass without structured resistance exercise, especially for individuals with existing sarcopenia.⁸ 

2. Protein intake must be a priority.

Because GLP-1 medications suppress appetite, meeting protein targets requires deliberate effort. Adequate protein supplies the amino acids necessary for muscle maintenance, reducing the body's need to break down existing tissue for fuel. 

3. Support muscle from the inside out.

Beyond exercise and diet, emerging research points to a third lever, the gut, as a meaningful factor in how the body builds and preserves muscle. A connection increasingly relevant for anyone undergoing GLP-1 treatment. 

The Gut-Muscle Connection 

The gut and skeletal muscle exist in constant communication, a relationship known as the gut-muscle connection. Gut bacteria shape inflammatory response, nutrient absorption, and the signaling pathways that determine whether muscle grows or breaks down. Among the most influential signals are short-chain fatty acids, metabolic byproducts of gut bacteria that directly affect muscle metabolism.¹⁰ 

As people age, the number of those short-chain fatty acid-producing bacteria decline, resulting in a short-chain fatty acid deficiency that has been linked to the development of sarcopenia.10 This dynamic matters for GLP-1 users in two distinct ways. 

First, the medications may improve gut microbiome composition: studies tracking liraglutide and similar drugs show a positive shift toward microbial profiles associated with metabolic improvement.¹¹ 

Second, a well-functioning gut provides the physiological foundation for how the body produces insulin and GLP-1 in response to meals. Supporting gut health through targeted postbiotic and probiotic therapies may reinforce the body's own metabolic regulation.¹² 

This is where next-generation probiotics enter the conversation. Akkermansia muciniphila, a naturally occurring gut bacterium, has drawn significant scientific attention for its functional relationship to both gut and muscle health, supporting weight management through the microbiome.13

Spindle Muscle+ is powered by Akkermansia MYO™, a postbiotic ingredient derived from this strain. In a 12-week randomized, double-blind, placebo-controlled study of healthy, exercising adults not taking GLP-1 medications, supplementation produced statistically significant improvements: 

  • Lower leg strength improved more than 10% versus placebo, with implications for balance, mobility, and functional independence.

  • Handgrip strength improved more than 5% versus placebo, reflecting gains relevant to everyday tasks.

  • Key biomarkers shifted favorably, with increased IGF-1 and prealbumin (markers of muscle maintenance) and decreased myostatin, a protein that promotes muscle breakdown when elevated.

Akkermansia MYO™ is the only Akkermansia strain clinically proven to support muscle strength and muscle mass retention. Used alongside GLP-1 medications, (with a healthcare provider's guidance), it may help address lean muscle loss during the metabolic and lifestyle shifts that accompany both weight loss and natural aging, supporting broader metabolic resilience along the way. 

The Bottom Line

Muscle loss is a recognized, manageable side effect of rapid weight loss on GLP-1 medications — not an inevitable one. A comprehensive approach combining resistance training, adequate protein, and gut health support can help preserve strength and functional capacity while the medication delivers its intended metabolic benefits. 

The science surrounding GLP-1 medications continues to evolve, and anyone with concerns about side effects should consult their physician. For those interested in a muscle-preservation strategy, Akkermansia MYO™ in Spindle Muscle+ is clinically proven to support muscle strength and help maintain it with age.

Shop Spindle Muscle+

References

  1. Yang, H. Journal of Clinical Medicine. 2025, 14(19), 6758

  2. Latif, W. et al. StatPearls Publishing. 2026 Jan.

  3. Janssen, T. et al. Current Opinion in Clinical Nutrition and Metabolic Care. 26(6):p 521-527, November 2023. 

  4. Chavez, A. et al. Current Opinion in Clinical Nutrition and Metabolic Care. 28(4):p 351-357, July 2025. 

  5. Williams, S. Stanford Medicine News Center. June 2, 2026

  6. Shaooli, R., The American Journal of Medicine. 2026

  7. Yuan, S. et al. Metabolism Clinical and Experimental. Volume 144, 155533, July 2023.

  8. Fang, J. et al. Frontiers in Microbiology, 07 October 2025. Volume 16 - 2025 

  9. Kamath, S., et al. British Journal of Clinical Pharmacology, February 2026.

  10. Dutta, S. et al. Systems Biology. July 2025, Vol 123: 12.

  11. Depommier, C. et al. Nature Medicine. 25, 1096-1103 (2019)



Glossary

  • Fat-free mass: The portion of body weight that isn't fat, including muscle, bone, water, and organ tissue; a key metric in assessing body composition changes during weight loss.

  • Glycemic control: The regulation of blood sugar levels within a healthy range, a primary treatment goal for type 2 diabetes.

  • GLP-1 (glucagon-like peptide-1): A natural gut hormone released after eating that stimulates insulin secretion, slows digestion, and signals fullness. GLP-1 receptor agonist medications mimic this hormone to treat type 2 diabetes and obesity.

  • Gut-muscle connection: The bidirectional communication network between intestinal microbiota and skeletal muscle, mediated by metabolic, hormonal, and immune signaling.

  • Gut microbiome: The community of microorganisms living in the digestive tract that influence digestion, immunity, inflammation, and metabolic health.

  • IGF-1 (Insulin-like Growth Factor 1): A hormone that stimulates cell growth and plays a key role in muscle development and maintenance.

  • Myostatin: A protein that inhibits muscle growth and development; elevated levels are associated with accelerated muscle loss.

  • Postbiotic: Inactivated microorganisms or their components that confer a health benefit, distinct from live probiotics.

  • Prealbumin: A blood protein used as a short-term marker that reflects nutritional status and protein adequacy, relevant in clinical studies examining muscle health and tissue maintenance.

  • Sarcopenia: The progressive, age-related loss of skeletal muscle mass and strength, now recognized as a clinical muscle disorder.

  • Short-chain fatty acids: Metabolic byproducts produced by gut bacteria during fiber fermentation that influence inflammation, energy metabolism, and muscle health.